Klippel-Trenaunay-Weber Syndrome
|
0.580 |
GeneticVariation
|
disease |
BEFREE |
Haploinsufficiency of Klippel-Trenaunay syndrome gene Aggf1 inhibits developmental and pathological angiogenesis by inactivating PI3K and AKT and disrupts vascular integrity by activating VE-cadherin.
|
27522498 |
2016 |
Klippel-Trenaunay-Weber Syndrome
|
0.580 |
AlteredExpression
|
disease |
BEFREE |
We have previously reported that upregulation of angiogenic factor AGGF1 is associated with KTS, but the molecular mechanism is not clear.
|
23197652 |
2013 |
Klippel-Trenaunay-Weber Syndrome
|
0.580 |
Biomarker
|
disease |
BEFREE |
AGGF1 is an angiogenic factor, and its deregulation is associated with a vascular malformation consistent with Klippel-Trenaunay syndrome (KTS).
|
19556247 |
2009 |
Klippel-Trenaunay-Weber Syndrome
|
0.580 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that common AGGF1 variants confer risk of KTS.
|
18564129 |
2008 |
Klippel-Trenaunay-Weber Syndrome
|
0.580 |
SusceptibilityMutation
|
disease |
ORPHANET |
These results suggest that common AGGF1 variants confer risk of KTS.
|
18564129 |
2008 |
Klippel-Trenaunay-Weber Syndrome
|
0.580 |
GeneticVariation
|
disease |
BEFREE |
The findings bring into question the assertion that VG5Q, E133K is a mutation and that it causes KTS.
|
16443853 |
2006 |
Klippel-Trenaunay-Weber Syndrome
|
0.580 |
Biomarker
|
disease |
BEFREE |
AGGF1 encodes a potent angiogenic factor, and KTS-associated mutations enhance angiogenic activity of AGGF1, defining 'increased angiogenesis' as one molecular mechanism for the pathogenesis of KTS.
|
15905966 |
2005 |
Klippel-Trenaunay-Weber Syndrome
|
0.580 |
Biomarker
|
disease |
BEFREE |
These genes include AGGF1 for Klippel-Trenaunay syndrome, RASA1 for capillary malformations, KRIT1, MGC4607, PDCD10 for cerebral cavernous malformations, glomulin for glomuvenous malformations, TIE2 for multiple cutaneous and mucosal venous malformations, VEGFR-3, FOXC2, NEMO, SOX18 for lymphedema or related syndromes, ENG, ACVRLK1, MADH4 for HHT or related syndromes, NDP for Coats' disease, Notch3 for CADASIL, and PTEN for Proteus Syndrome.
|
16379592 |
2005 |
Klippel-Trenaunay-Weber Syndrome
|
0.580 |
Biomarker
|
disease |
BEFREE |
Here we use human genetics as an approach to identify an angiogenic factor, VG5Q, and further define two genetic defects of VG5Q in patients with the vascular disease Klippel-Trenaunay syndrome (KTS).
|
14961121 |
2004 |
Klippel-Trenaunay-Weber Syndrome
|
0.580 |
GeneticVariation
|
disease |
UNIPROT |
Here we use human genetics as an approach to identify an angiogenic factor, VG5Q, and further define two genetic defects of VG5Q in patients with the vascular disease Klippel-Trenaunay syndrome (KTS).
|
14961121 |
2004 |
Congestive heart failure
|
0.110 |
Biomarker
|
disease |
BEFREE |
Here the authors uncover a pathway whereby AGGF1 blocks ER stress by inhibiting ERK1/2 activation and the transcriptional repressor ZEB1, leading to induction of miR-183-5p and down-regulation of CHOP, and show that AGGF1 can effectively treat cardiac hypertrophy and heart failure.
|
28743963 |
2017 |
Congestive heart failure
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
Ascites
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Cellulitis
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Anomalous pulmonary artery
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Patent ductus arteriosus
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Gastrointestinal Hemorrhage
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Atrial Septal Defects
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Hemangioma
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Hematuria
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Hepatomegaly
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Hydrops Fetalis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Leg Length Inequality
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Microcephaly
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Pulmonary Embolism
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|